文献速递生殖医学

利用国家体外受精登记数据验证医保覆盖的体外受精临床结局

Using national in vitro fertilization registries to validate clinical outcomes after in vitro fertilization covered by health insurance.
PubMed 文献 · Fertil Steril · 2024-12-12

本研究为回顾性队列研究,使用2005-2020年美国Optum去标识化Clinformatics Data Mart数据库(CDM)中20-44岁接受体外受精(IVF)的女性数据,将CDM中IVF周期及妊娠、活产、活产类型(单胎、双胎、三胎及以上)率与SART国家IVF登记数据进行比较。结果显示各年度结局率与SART数据相似,例如2020年首次胚胎移植后妊娠率CDM为62.03%(95%CI 59.48-64.47),SART为64.96%。结论认为CDM可准确识别医保覆盖的IVF周期及关键临床结局。

要点

  • CDM数据库每年识别出超过3,000个IVF周期,2005-2020年各年临床结局率与SART登记数据相似。
  • 2020年首次胚胎移植后妊娠率CDM为62.03%(95%CI 59.48-64.47),SART为64.96%。
  • 2020年首次胚胎移植后活产率CDM为44.58%(95%CI 41.90-47.21),SART为46.95%。

核心结论

  • CDM可准确识别医保覆盖的IVF周期及妊娠率、活产率和活产类型等关键临床结局,报告率与国家IVF临床登记数据相似。
  • 研究结果支持CDM是研究IVF保险覆盖的稳健数据源,可准确评估IVF临床结局。
  • 考虑IVF保险覆盖的政策制定者可使用CDM模拟和测量新的或现有IVF保险覆盖政策的影响。

研究设计与样本

  • 回顾性队列研究,使用2005-2020年Optum去标识化Clinformatics Data Mart数据库(CDM)。
  • 研究对象为2005-2020年接受IVF的美国20-44岁女性。
  • 暴露为接受IVF。
  • 主要结局指标为IVF周期数及妊娠率(包括流产和终止妊娠)、活产率和活产类型(单胎、双胎、三胎及以上)。

主要发现

  • 2005-2020年每年在CDM中识别出超过3,000个IVF周期。
  • 2020年首次胚胎移植后妊娠率CDM为62.03%(95%CI 59.48-64.47),SART为64.96%。
  • 2020年首次胚胎移植后活产率CDM为44.58%(95%CI 41.90-47.21),SART为46.95%。
  • 2020年单胎出生率CDM为94.17%(95%CI 92.24-96.10),SART为94.37%。
  • 2020年双胎出生率CDM为5.48%(95%CI 3.60-7.35),SART为5.46%;三胎及以上出生率CDM为0.35%(95%CI 0.00-0.84),SART为0.17%。

临床怎么用

  • 作者认为CDM可准确识别医保覆盖的IVF周期及关键临床结局,其报告率与国家IVF临床登记数据相似。
  • 作者认为CDM是研究IVF保险覆盖的稳健数据源,可准确评估IVF临床结局。
  • 作者指出考虑IVF保险覆盖的政策制定者可使用CDM模拟和测量新的或现有IVF保险覆盖政策的影响。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To evaluate in vitro fertilization (IVF) cycles covered by health insurance using a national commercial claims database and validate key clinical events against national IVF registries. DESIGN: Retrospective cohort study. SUBJECTS: US women aged 20-44 years who underwent IVF from 2005-2020 in Optum's deidentified Clinformatics Data Mart Database (CDM). EXPOSURE: Undergoing IVF. MAIN OUTCOME MEASURES: In vitro fertilization cycles and rates of pregnancies (inclusive of losses and terminations), live births, and live birth types (e.g., singleton, twin, and triplet or higher-order). RESULTS: We identified more than 3,000 IVF cycles in each year from 2005-2020 within CDM. When comparing our rates of clinical outcomes with external benchmark data, the results were similar across all the years of our study. For example, in 2020, the percentages of pregnancies after first embryo transfer were 62.03% (95% confidence interval [CI], 59.48-64.47) in CDM and 64.96% in data from the Society for Assisted Reproductive Technology (SART). The rates of live birth after first embryo transfer were 44.58% (95% CI, 41.90-47.21) in CDM in 2020 and 46.95% in SART in 2020. The rate of singleton births was 94.17% (95% CI, 92.24-96.10) in CDM in 2020, and this rate was 94.37% in SART in 2020. For twin births, the rates were 5.48% (95% CI, 3.60-7.35) in CDM in 2020 and 5.46% in SART in 2020. The rates of triplet or higher-order births were 0.35% (95% CI, 0.00-0.84) in CDM in 2020 and 0.17% in SART in 2020. CONCLUSION: We found that CDM can be used to accurately identify IVF cycles covered by insurance and key clinical outcomes such as rates of pregnancies, live births, and live birth types, and our reported rates were similar to national IVF clinical registry data. Our findings support that CDM is a robust data source to conduct research about IVF insurance coverage and can accurately evaluate clinical outcomes resulting from IVF. Policymakers who are considering insurance coverage for IVF can use CDM to model and measure the impact of new or existing policies for IVF insurance coverage.

来源:Fertil Steril,查看原文。版权归原作者所有。

引用

  1. Suh D, Yan P, Dunn RL, et al. Using national in vitro fertilization registries to validate clinical outcomes after in vitro fertilization covered by health insurance. Fertil Steril. 2024. PMID: 39674336. doi:10.1016/j.fertnstert.2024.12.015

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。